Weight MaintenanceAFTER-GLPNCT07701460
Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
A study testing Digital Behavioral Application in people with Weight Maintenance, run by Tufts University at 1 site in United States.
Trial summary
Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Weight Maintenance
- What is being tested?
- Digital Behavioral Application
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteUnited States
- Study dates
- 15 Oct 2026to 31 Jul 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years of age or older (no upper limit);
- ability to read, write, and speak English and/or Spanish;
- ability to provide informed consent;
- less than 30-days since GLP-1 RA cessation;
- willing to participate.
Who cannot join
- No clinically significant weight loss (e.g., < 5% body weight) while taking GLP medication;
- major psychiatric illness, cognitive impairment, or substance misuse that could impair ability to participate;
- medical conditions that significantly affect weight or make participation unsafe (e.g., pregnancy or breastfeeding, recent bariatric surgery, current use of GLP 1 or other anti-obesity medications, or endocrine disorders that alter weight regulation);
- inability to use a smartphone or complete remote study procedures;
- participation in another weight loss or maintenance program or clinical trial judged by investigators to interfere with study involvement;
- Adults unable to consent (cognitively impaired);
- Wards of the state;
- Anyone under age 18.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site
This study is conducted remotely
Boston, Massachusetts, 02111
About this study
Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging. Researchers at Tufts University are conducting a study to learn whether a digital lifestyle program can help people maintain their weight loss after they stop taking a GLP-1 medication.
Adults who have recently stopped a GLP-1 medication may be eligible to participate. Participants will be randomly assigned to either receive access to a digital program or to continue with usual care. The study lasts 12 months and is fully remote. All participants will receive a Bluetooth scale to track weight from home and will complete short online questionnaires several times over the year.
By taking part, participants can help researchers better understand how to support long-term weight maintenance in a way that is affordable, accessible, and sustainable. Participants are compensated for their time, and involvement may help improve care for others with similar experiences.
- Conditions
- Weight Maintenance
- Being tested
- Digital Behavioral Application
- Keywords
- Obesity, Overweight, Glucagon-Like Peptide-1 Receptor Agonists, Digital Health, Lifestyle Intervention, Mobile Applications, Weight Maintenance, Eating Behavior
- Medical subject headings
- Obesity, Overweight, Feeding Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Digital Behavioral ApplicationBehavioural
Noom® provides well-established behavioral strategies for weight loss and weight maintenance, such as self-monitoring of diet, exercise, and weight. What Noom® adds is education on the physiological, psychological, social, and environmental factors that influence eating behavior and tools that increase self-efficacy for dealing with those stimuli. For example, Noom® has a lesson that defines social triggers, explains the influence social triggers have on motivation to eat, and asks the participant to identify their own social triggers and a plan for managing triggers should they come up. Then the app prompts participants to report back on how they managed or struggled to manage a trigger and responds accordingly. Participants will be prescribed 15 minutes of use per day per Noom® recommendations, which includes interactive lessons, food logging, and weigh-ins.
| Study group | Role | What they receive |
|---|---|---|
| Noom® Smart device Application Subscription | Experimental | Not described Receives: Behavioral: Digital Behavioral Application |
| Usual care | No intervention | Usual care for weight loss maintenance includes ongoing nutrition, exercise, and lifestyle counseling. However, the implementation of this standard of care is highly variable and dependent on the provider's discretion and availability. In many cases it is nothing. In some cases, the patient may have 1-2 office or remote visits with a provider or dietitian who educates the patient on nutrition and exercise behaviors. "Usual care" is left to each providers' discretion and will identify how much counseling (if any) participants receive through self-report. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of weight loss maintained
Percentage of weight loss maintained over 12 months following GLP-1 medication cessation measured using study-provided Bluetooth scale.
Measured: 12-months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2026
- Study start15 Oct 2026 (estimated)
- Primary completion31 Jan 2028 (estimated)
- Study completion31 Jul 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Weight MaintenanceStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Factorial
- Model description
- This is a 2-arm parallel group open-label randomized controlled trial (RCT) with randomization stratified on 3 factors: (1) prior use of digital behavioral support (Y/N); (2) amount of weight loss (kg) while on GLP-1 (5-10% body weight vs. \>10% body weight); and (3) weight status (with vs without obesity, obesity defined as BMI ≥ 25).
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Tufts University
- Sponsor type
- University, hospital or other
- Collaborators
- Noom Inc.
- Responsible party
- Sponsor
- Investigators
- Kelseanna Hollis-Hansen, PhD, MPH, Principal investigator, Tufts University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07701460
- Sponsor's protocol ID
- STUDY00007074
- Acronym
- AFTER-GLP
- Status last verified
- Jul 2026
- First submitted
- 8 Jul 2026
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Sharing of IPD will be at the discretion of the funder.
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing Follow up Trajectories in Eating, Routines, and Weight After GLP-1
- ClinicalTrials.gov ID
- NCT07701460
- Acronym / sponsor ID
- AFTER-GLP / STUDY00007074
- Conditions
- Weight Maintenance
- Keywords
- Obesity, Overweight, Glucagon-Like Peptide-1 Receptor Agonists, Digital Health, Lifestyle Intervention, Mobile Applications, Weight Maintenance, Eating Behavior
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Tufts UniversityUniversity, hospital or other
- Collaborators
- Noom Inc.
- Study start
- 15 Oct 2026 (estimated)
- Primary completion
- 31 Jan 2028 (estimated)
- Study completion
- 31 Jul 2028 (estimated)
- First posted
- 14 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Many people who use GLP-1 medications (such as semaglutide or tirzepatide) achieve meaningful weight loss, but maintaining that weight loss off after stopping the medication can be very challenging. Researchers at Tufts University are conducting a study to learn whether a digital lifestyle program can help people maintain their weight loss after they stop taking a GLP-1 medication.
Adults who have recently stopped a GLP-1 medication may be eligible to participate. Participants will be randomly assigned to either receive access to a digital program or to continue with usual care. The study lasts 12 months and is fully remote. All participants will receive a Bluetooth scale to track weight from home and will complete short online questionnaires several times over the year.
By taking part, participants can help researchers better understand how to support long-term weight maintenance in a way that is affordable, accessible, and sustainable. Participants are compensated for their time, and involvement may help improve care for others with similar experiences.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Factorial
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
- Model description
- This is a 2-arm parallel group open-label randomized controlled trial (RCT) with randomization stratified on 3 factors: (1) prior use of digital behavioral support (Y/N); (2) amount of weight loss (kg) while on GLP-1 (5-10% body weight vs. >10% body weight); and (3) weight status (with vs without obesity, obesity defined as BMI ≥ 25).
| Arm | Type | Receives |
|---|---|---|
| Noom® Smart device Application Subscription | Experimental | Behavioral: Digital Behavioral Application |
| Usual care | No intervention | –Usual care for weight loss maintenance includes ongoing nutrition, exercise, and lifestyle counseling. However, the implementation of this standard of care is highly variable and dependent on the provider's discretion and availability. In many cases it is nothing. In some cases, the patient may have 1-2 office or remote visits with a provider or dietitian who educates the patient on nutrition and exercise behaviors. "Usual care" is left to each providers' discretion and will identify how much counseling (if any) participants receive through self-report. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- 18 years of age or older (no upper limit);
- ability to read, write, and speak English and/or Spanish;
- ability to provide informed consent;
- less than 30-days since GLP-1 RA cessation;
- willing to participate.
Key exclusion criteria (8 listed)
- No clinically significant weight loss (e.g., < 5% body weight) while taking GLP medication;
- major psychiatric illness, cognitive impairment, or substance misuse that could impair ability to participate;
- medical conditions that significantly affect weight or make participation unsafe (e.g., pregnancy or breastfeeding, recent bariatric surgery, current use of GLP 1 or other anti-obesity medications, or endocrine disorders that alter weight regulation);
- inability to use a smartphone or complete remote study procedures;
- participation in another weight loss or maintenance program or clinical trial judged by investigators to interfere with study involvement;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Digital Behavioral ApplicationNoom® provides well-established behavioral strategies for weight loss and weight maintenance, such as self-monitoring of diet, exercise, and weight. What Noom® adds is education on the physiological, psychological, social, and environmental factors that influence eating behavior and tools that increase self-efficacy for dealing with those stimuli. For example, Noom® has a lesson that defines social triggers, explains the influence social triggers have on motivation to eat, and asks the participant to identify their own social triggers and a plan for managing triggers should they come up. Then the app prompts participants to report back on how they managed or struggled to manage a trigger and responds accordingly. Participants will be prescribed 15 minutes of use per day per Noom® recommendations, which includes interactive lessons, food logging, and weigh-ins. | Behavioural | Noom® Smart device Application Subscription |
Primary outcome
Percentage of weight loss maintained
Time frame: 12-months
Percentage of weight loss maintained over 12 months following GLP-1 medication cessation measured using study-provided Bluetooth scale.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: No. Sharing of IPD will be at the discretion of the funder.
Related trials for Weight Maintenance
RecruitingPhase 4
Remimazolam Versus Propofol for Maintenance of Anaesthesia During Major Hepatectomy Under Low Central Venous Pressure
Intraoperative Hypotension, Hepatectomy
RecruitingObservational study
Asprosin and miRNA Expression in Young Women With Metabolic Syndrome
Metabolic Syndrome, Insulin Resistance
Recruiting
Time Restricted Eating for WeIght LoSs MainTenance-2
Weight Loss, Weight Gain
RecruitingPhase 2
Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
Overweight , Obesity, Adults
Active, not recruiting
Effects of a High-protein Diet and Resistance Training on Fat-mass Loss Maintenance
Obesity (Body Mass Index >30 kg/m2)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Kelseanna Hollis-Hansen, PhD, MPH principal investigator
Tufts University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Digital Behavioral Application in people with Weight Maintenance, run by Tufts University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact NICHE Lab Study Team ((857) 267-6055, afterglp@tufts.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of weight loss maintained (time frame: 12-months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.